Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior mandible (Type II bone) in dogs

Ulf M E Wikesjö, Andreas V. Xiropaidis, Mohammed Qahash, Won Hee Lim, Rachel G. Sorensen, Michael D. Rohrer, John M. Wozney, Jan Hall

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background: Conventional oral/maxillofacial implants reach osseointegration over several months during which the titanium fixtures interact with alveolar bone. The objective of this study was to determine if adsorbing recombinant human bone morphogenetic protein-2 (rhBMP-2) onto a titanium porous oxide (TPO) implant surface might enhance or accelerate local bone formation and support osseointegration in a large animal oral/maxillofacial orthotopic model. Material and Methods: Endosseous implants with a TPO surface were installed into the edentulated posterior mandible in eight adult Hound Labrador mongrel dogs. The implant surface had been adsorbed with rhBMP-2 at 0.2 or 4.0 mg/ml. TPO implants without rhBMP-2 served as control. Treatments were randomized between jaw quadrants. Mucosal flaps were advanced and sutured leaving the implants submerged. Clinical and radiographic evaluations were made immediately post-surgery, at day 10 (suture removal), and week 4 and 8 post-surgery. The animals received fluorescent bone markers at week 3, 4, and at week 8 post-surgery, when they were euthanized for histologic analysis. Results: TPO implants coated with rhBMP-2 exhibited dose-dependent bone remodelling including immediate resorption and formation of implant adjacent bone, and early establishment of clinically relevant osseointegration. The resulting bone-implant contact, although clinically respectable, appeared significantly lower for rhBMP-2-coated implants compared with the control [rhBMP-2 (0.2 mg/ml) 43.3±10.8% versus 71.7±7.8%, p<0.02; rhBMP-2 (4.0 mg/ml) 35.4±10.6% versus 68.2±11.0%, p<0.03]. Conclusions: rhBMP-2 adsorbed onto TPO implant surfaces initiates dose-dependent peri-implant bone re-modelling resulting in the formation of normal, physiologic bone and clinically relevant osseointegration within 8 weeks.

Original languageEnglish (US)
Pages (from-to)985-991
Number of pages7
JournalJournal of Clinical Periodontology
Volume35
Issue number11
DOIs
StatePublished - Nov 1 2008

Fingerprint

Titanium
Mandible
Osteogenesis
Dogs
Osseointegration
Bone and Bones
Newfoundland and Labrador
recombinant human bone morphogenetic protein-2
Bone Remodeling
Jaw
Ambulatory Surgical Procedures
Sutures
titanium dioxide

Keywords

  • Bone morphogenetic protein
  • Dental/oral implants
  • Dogs
  • Osseointegration
  • Porous titanium oxide
  • Tissue engineering
  • Titanium
  • rhBMP-2

ASJC Scopus subject areas

  • Periodontics

Cite this

Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior mandible (Type II bone) in dogs. / Wikesjö, Ulf M E; Xiropaidis, Andreas V.; Qahash, Mohammed; Lim, Won Hee; Sorensen, Rachel G.; Rohrer, Michael D.; Wozney, John M.; Hall, Jan.

In: Journal of Clinical Periodontology, Vol. 35, No. 11, 01.11.2008, p. 985-991.

Research output: Contribution to journalArticle

Wikesjö, Ulf M E ; Xiropaidis, Andreas V. ; Qahash, Mohammed ; Lim, Won Hee ; Sorensen, Rachel G. ; Rohrer, Michael D. ; Wozney, John M. ; Hall, Jan. / Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior mandible (Type II bone) in dogs. In: Journal of Clinical Periodontology. 2008 ; Vol. 35, No. 11. pp. 985-991.
@article{438784a3b1cd4c6cb6405486661f8884,
title = "Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior mandible (Type II bone) in dogs",
abstract = "Background: Conventional oral/maxillofacial implants reach osseointegration over several months during which the titanium fixtures interact with alveolar bone. The objective of this study was to determine if adsorbing recombinant human bone morphogenetic protein-2 (rhBMP-2) onto a titanium porous oxide (TPO) implant surface might enhance or accelerate local bone formation and support osseointegration in a large animal oral/maxillofacial orthotopic model. Material and Methods: Endosseous implants with a TPO surface were installed into the edentulated posterior mandible in eight adult Hound Labrador mongrel dogs. The implant surface had been adsorbed with rhBMP-2 at 0.2 or 4.0 mg/ml. TPO implants without rhBMP-2 served as control. Treatments were randomized between jaw quadrants. Mucosal flaps were advanced and sutured leaving the implants submerged. Clinical and radiographic evaluations were made immediately post-surgery, at day 10 (suture removal), and week 4 and 8 post-surgery. The animals received fluorescent bone markers at week 3, 4, and at week 8 post-surgery, when they were euthanized for histologic analysis. Results: TPO implants coated with rhBMP-2 exhibited dose-dependent bone remodelling including immediate resorption and formation of implant adjacent bone, and early establishment of clinically relevant osseointegration. The resulting bone-implant contact, although clinically respectable, appeared significantly lower for rhBMP-2-coated implants compared with the control [rhBMP-2 (0.2 mg/ml) 43.3±10.8{\%} versus 71.7±7.8{\%}, p<0.02; rhBMP-2 (4.0 mg/ml) 35.4±10.6{\%} versus 68.2±11.0{\%}, p<0.03]. Conclusions: rhBMP-2 adsorbed onto TPO implant surfaces initiates dose-dependent peri-implant bone re-modelling resulting in the formation of normal, physiologic bone and clinically relevant osseointegration within 8 weeks.",
keywords = "Bone morphogenetic protein, Dental/oral implants, Dogs, Osseointegration, Porous titanium oxide, Tissue engineering, Titanium, rhBMP-2",
author = "Wikesj{\"o}, {Ulf M E} and Xiropaidis, {Andreas V.} and Mohammed Qahash and Lim, {Won Hee} and Sorensen, {Rachel G.} and Rohrer, {Michael D.} and Wozney, {John M.} and Jan Hall",
year = "2008",
month = "11",
day = "1",
doi = "10.1111/j.1600-051X.2008.01318.x",
language = "English (US)",
volume = "35",
pages = "985--991",
journal = "Journal of Clinical Periodontology",
issn = "0303-6979",
publisher = "Blackwell Munksgaard",
number = "11",

}

TY - JOUR

T1 - Bone formation at recombinant human bone morphogenetic protein-2-coated titanium implants in the posterior mandible (Type II bone) in dogs

AU - Wikesjö, Ulf M E

AU - Xiropaidis, Andreas V.

AU - Qahash, Mohammed

AU - Lim, Won Hee

AU - Sorensen, Rachel G.

AU - Rohrer, Michael D.

AU - Wozney, John M.

AU - Hall, Jan

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Background: Conventional oral/maxillofacial implants reach osseointegration over several months during which the titanium fixtures interact with alveolar bone. The objective of this study was to determine if adsorbing recombinant human bone morphogenetic protein-2 (rhBMP-2) onto a titanium porous oxide (TPO) implant surface might enhance or accelerate local bone formation and support osseointegration in a large animal oral/maxillofacial orthotopic model. Material and Methods: Endosseous implants with a TPO surface were installed into the edentulated posterior mandible in eight adult Hound Labrador mongrel dogs. The implant surface had been adsorbed with rhBMP-2 at 0.2 or 4.0 mg/ml. TPO implants without rhBMP-2 served as control. Treatments were randomized between jaw quadrants. Mucosal flaps were advanced and sutured leaving the implants submerged. Clinical and radiographic evaluations were made immediately post-surgery, at day 10 (suture removal), and week 4 and 8 post-surgery. The animals received fluorescent bone markers at week 3, 4, and at week 8 post-surgery, when they were euthanized for histologic analysis. Results: TPO implants coated with rhBMP-2 exhibited dose-dependent bone remodelling including immediate resorption and formation of implant adjacent bone, and early establishment of clinically relevant osseointegration. The resulting bone-implant contact, although clinically respectable, appeared significantly lower for rhBMP-2-coated implants compared with the control [rhBMP-2 (0.2 mg/ml) 43.3±10.8% versus 71.7±7.8%, p<0.02; rhBMP-2 (4.0 mg/ml) 35.4±10.6% versus 68.2±11.0%, p<0.03]. Conclusions: rhBMP-2 adsorbed onto TPO implant surfaces initiates dose-dependent peri-implant bone re-modelling resulting in the formation of normal, physiologic bone and clinically relevant osseointegration within 8 weeks.

AB - Background: Conventional oral/maxillofacial implants reach osseointegration over several months during which the titanium fixtures interact with alveolar bone. The objective of this study was to determine if adsorbing recombinant human bone morphogenetic protein-2 (rhBMP-2) onto a titanium porous oxide (TPO) implant surface might enhance or accelerate local bone formation and support osseointegration in a large animal oral/maxillofacial orthotopic model. Material and Methods: Endosseous implants with a TPO surface were installed into the edentulated posterior mandible in eight adult Hound Labrador mongrel dogs. The implant surface had been adsorbed with rhBMP-2 at 0.2 or 4.0 mg/ml. TPO implants without rhBMP-2 served as control. Treatments were randomized between jaw quadrants. Mucosal flaps were advanced and sutured leaving the implants submerged. Clinical and radiographic evaluations were made immediately post-surgery, at day 10 (suture removal), and week 4 and 8 post-surgery. The animals received fluorescent bone markers at week 3, 4, and at week 8 post-surgery, when they were euthanized for histologic analysis. Results: TPO implants coated with rhBMP-2 exhibited dose-dependent bone remodelling including immediate resorption and formation of implant adjacent bone, and early establishment of clinically relevant osseointegration. The resulting bone-implant contact, although clinically respectable, appeared significantly lower for rhBMP-2-coated implants compared with the control [rhBMP-2 (0.2 mg/ml) 43.3±10.8% versus 71.7±7.8%, p<0.02; rhBMP-2 (4.0 mg/ml) 35.4±10.6% versus 68.2±11.0%, p<0.03]. Conclusions: rhBMP-2 adsorbed onto TPO implant surfaces initiates dose-dependent peri-implant bone re-modelling resulting in the formation of normal, physiologic bone and clinically relevant osseointegration within 8 weeks.

KW - Bone morphogenetic protein

KW - Dental/oral implants

KW - Dogs

KW - Osseointegration

KW - Porous titanium oxide

KW - Tissue engineering

KW - Titanium

KW - rhBMP-2

UR - http://www.scopus.com/inward/record.url?scp=54049088977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049088977&partnerID=8YFLogxK

U2 - 10.1111/j.1600-051X.2008.01318.x

DO - 10.1111/j.1600-051X.2008.01318.x

M3 - Article

C2 - 18976395

AN - SCOPUS:54049088977

VL - 35

SP - 985

EP - 991

JO - Journal of Clinical Periodontology

JF - Journal of Clinical Periodontology

SN - 0303-6979

IS - 11

ER -